Drug Trial Radar · NCT06268613
A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy
Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
163
Actual
Start
Jan 16, 2024
Primary completion
Feb 19, 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- Samsung Bioepis Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to compare the amount of study drug in patients' blood to confirm that SB27 works in the same way as EU and US sourced Keytruda in early or locally advanced non-small cell lung cancer (NSCLC) patients who underwent surgery and adjuvant chemotherapy. The main question it aims to answer is: • What the body does to the study drug, which is called "pharmacokinetic" Participants will receive investigational product (IP) administration every 3 weeks, maximum 18 cycles over about 51 weeks and blood sample will be collected. Researchers will compare 3 medicines (SB27, EU sourced Keytruda, and US sourced Keytruda) to see if SB27 works in the same way as EU and US sourced Keytruda.
Conditions
- Non-small Cell Lung Cancer Stage II
- Non-small Cell Lung Cancer Stage IIIA
Interventions
SB27Drug
Will be administered intravenously at a fixed dose of 200 mg every 3 weeks, maximum 18 cycles over about 51 weeks
EU sourced KeytrudaDrug
Will be administered intravenously at a fixed dose of 200 mg every 3 weeks, maximum 18 cycles over about 51 weeks
US sourced KeytrudaDrug
Will be administered intravenously at a fixed dose of 200 mg every 3 weeks, maximum 18 cycles over about 51 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Concentration-time Curve (AUC) over the Dosing Interval at Cycle 1Time frame: At the end of Cycle 1 (each cycle is 21 days)
- Area Under the Concentration-time Curve (AUC) over the Dosing Interval at Cycle 6Time frame: At the end of Cycle 6 (each cycle is 21 days)
Locations
24 sites in 4 countries. Site status is shown where the registry gives one.
SB Investigative Site
Gdansk, Poland
SB Investigative Site
Otwock, Poland
SB Investigative Site
Ansan, South Korea
SB Investigative Site
Busan, South Korea
SB Investigative Site
Daegu, South Korea
SB Investigative Site
Hwasun, South Korea
SB Investigative Site
Incheon, South Korea
SB Investigative Site
Jinju, South Korea
SB Investigative Site
Seongnam, South Korea
SB Investigative Site 3
Seoul, South Korea
SB Investigative Site 4
Seoul, South Korea
SB Investigative Site 5
Seoul, South Korea
SB Investigative Site 6
Seoul, South Korea
SB Investigative Site 1
Suwon, South Korea
SB Investigative Site 2
Suwon, South Korea
SB Investigative Site
Ulsan, South Korea
SB Investigative Site
Málaga, Spain
SB Investigative Site
Jaén, Jaén, Spain
SB Investigative Site
A Coruña, Santiago de Compostela, Spain
SB Investigative Site
Adana, Turkey (Türkiye)
SB Investigative Site 1
Ankara, Turkey (Türkiye)
SB Investigative Site 2
Ankara, Turkey (Türkiye)
SB Investigative Site
Istanbul, Turkey (Türkiye)
SB Investigative Site
Izmir, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.